Table 2 Distribution of dopamine replacement therapy according to patient age a
Patient age | Therapy | 2007 | Year 2011 |
|---|---|---|---|
Age <65 years | DA monotherapy, n (%) | 10 (50%) | 14 (61%) |
Daily LD equivalents, mg (mean ± SD) | 245 ± 52 | 281 ± 48 | |
LD monotherapy, n (%) | 3 (15%) | 2 (9%) | |
Daily mg (mean ± SD) | 274 ± 29 | 275 ± 15 | |
DA + LD combined therapy, n (%) | 7 (35%) | 7 (30%) | |
Total daily LD equivalents, mg (mean ± SD) | 385 ± 62 | 388 ± 70 | |
Age between 65 and 75 years | DA monotherapy, n (%) | 4 (14%) | 14 (45%)b |
Daily LD equivalents, mg (mean ± SD) | 250 ± 57 | 314 ± 53b | |
LD monotherapy, n (%) | 11 (37%) | 2 (6%)b | |
Daily dose, mg (mean ± SD) | 325 ± 50 | 350 ± 25 | |
DA + LD combined therapy, n (%) | 14 (47%) | 15 (49%) | |
Total daily LD equivalents, mg (mean ± SD) | 425 ± 40 | 415 ± 54 | |
Age >75 years | DA monotherapy, n (%) | 0 (0%) | 1 (6%) |
Daily LD equivalents, mg (mean ± SD) | 250 ± 0 | ||
LD monotherapy, n (%) | 4 (67%) | 11 (61%) | |
Daily dose, mg (mean ± SD) | 465 ± 28 | 450 ± 20 | |
DA + LD combined therapy, n (%) | 2 (33%) | 6 (33%) | |
Total daily LD equivalents, mg (mean ± SD) | 525 ± 25 | 530 ± 22 |